FDA Win Boosts Struggling Pharmaceutical Stock

Core Viewpoint - Novo Nordisk's stock is experiencing a rebound after FDA approval for its weight-loss drug Wegovy to treat liver disease, following a significant drop in its stock price earlier this month [1]. Group 1: Stock Performance - The stock is currently trading at $54.10, reflecting a 3.1% increase [1]. - The company faced a 21.8% decline on July 29, marking its worst drop on record, and is down 39% in 2025 [2]. - The $50 level is now acting as a support floor for the stock [2]. Group 2: Market Sentiment - Short-term traders are showing a put-bias, indicated by a Schaeffer's put/call open interest ratio (SOIR) of 1.10, which is in the 99th percentile of the past year [2]. - There is potential for upgrades, as 14 out of 20 brokerages currently have a "hold" or worse recommendation [3]. - The stock has historically outperformed volatility expectations, with a Schaeffer's Volatility Scorecard (SVS) of 87 out of 100 [3].